Novo at one point struck a deal with Hims to distribute Wegovy at a cheaper cash-pay price, but the drugmakers abruptly called off the deal in June and accused Hims of illegal mass compounding and deceptive marketing. Since then, speculation that Novo might sue Hims has lingered, with traders on Kalshi pegging the odds at about 24% by the end of the year
PlexusDx eliminates this risk: fixed pricing and no insurance dependence means you maintain consistent, immediate access regardless of claim status
Again, it is a conversation about why [GLP-1s] can be an effective and safe treatment, but people do need support and guidance. The bottom line
Pairing weight loss injections with healthy habits not only amplifies results but also fosters a comprehensive approach to weight management
Both medications are common SSRIs
In fact, GLP-1 agonists are the fastest growing class of diabetes medicines with a 36% five-year compound annual growth rate and accounting for 16% of prescriptions in 2023